The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

BIRC5  -  baculoviral IAP repeat containing 5

Homo sapiens

Synonyms: API4, Apoptosis inhibitor 4, Apoptosis inhibitor survivin, Baculoviral IAP repeat-containing protein 5, EPR-1, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of BIRC5

  • This expression profile suggested involvement of apoptosis regulators in astrocytoma tumorigenesis, but tumor progression was more closely associated with proliferative advantages of which BIRC5 nuclear expression appeared to be a manifestation [1].
  • In cell lines representing aggressive lymphomas, NF-kappaB inhibition resulted in a decrease in BIRC5/Survivin expression [2].
  • In parallel with this observation, BIRC5/Survivin expression was higher in Burkitt's lymphoma and diffuse large B-cell lymphoma than in non-tumoural germinal centre cells [2].
  • Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer [3]?
  • Gene copy number gain of BIRC5 was detected in 33.9% (150/227) of cases, which correlated significantly with high UICC stage and the presence of lymph node metastases (p = 0.003 and p = 0.001, respectively), but not with unfavorable patients' outcome (p > 0.05) in multivariate analysis [4].

High impact information on BIRC5


Biological context of BIRC5


Anatomical context of BIRC5


Associations of BIRC5 with chemical compounds

  • Decreases in CyclinB2 and BIRC5 mRNA induced by FK506 or retinoic acid, both of which exert potentiation of NGF-induced neurite outgrowth effects but with different mechanisms, also correlated with their neurite outgrowth activities [16].
  • Nonregulated ethylbenzene was detected in one soil sample from API 4, one from API 5 and two from API 1 [17].

Other interactions of BIRC5

  • A set of genes was identified whose expression correlates either with BIRC5/Survivin or with BCL2 [2].
  • These results suggest that p53 is functional in the absence of p14(ARF) in MPM and that targeting of the downstream apoptosis inhibitor survivin can sensitize to CDDP-induced apoptosis [18].
  • This study indicates that monitored natural attenuation may be a technically feasible and efficient means for plume control in API 1, 4 and 5, provided the plumes in API 4 and 5 are not expanding [17].
  • Here, we show that an antisense oligonucleotide to the apoptosis inhibitor survivin suppressed de novo expression of survivin in ECs by vascular endothelial cell growth factor (VEGF) [19].

Analytical, diagnostic and therapeutic context of BIRC5


  1. Apoptosis and proliferation markers in diffusely infiltrating astrocytomas: profiling of 17 molecules. Liu, X., Chen, N., Wang, X., He, Y., Chen, X., Huang, Y., Yin, W., Zhou, Q. J. Neuropathol. Exp. Neurol. (2006) [Pubmed]
  2. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. Tracey, L., Pérez-Rosado, A., Artiga, M.J., Camacho, F.I., Rodríguez, A., Martínez, N., Ruiz-Ballesteros, E., Mollejo, M., Martinez, B., Cuadros, M., Garcia, J.F., Lawler, M., Piris, M.A. J. Pathol. (2005) [Pubmed]
  3. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Span, P.N., Tjan-Heijnen, V.C., Heuvel, J.J., de Kok, J.B., Foekens, J.A., Sweep, F.C. Clin. Chem. (2006) [Pubmed]
  4. High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy. Freier, K., Pungs, S., Sticht, C., Flechtenmacher, C., Lichter, P., Joos, S., Hofele, C. Int. J. Cancer (2007) [Pubmed]
  5. In vivo immunosuppression by targeting a novel protease receptor. Duchosal, M.A., Rothermel, A.L., McConahey, P.J., Dixon, F.J., Altieri, D.C. Nature (1996) [Pubmed]
  6. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Li, F., Ackermann, E.J., Bennett, C.F., Rothermel, A.L., Plescia, J., Tognin, S., Villa, A., Marchisio, P.C., Altieri, D.C. Nat. Cell Biol. (1999) [Pubmed]
  7. Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo. Herbert, J., Bono, F., Herault, J., Avril, C., Dol, F., Mares, A., Schaeffer, P. J. Clin. Invest. (1998) [Pubmed]
  8. Inhibition of melanoma tumor growth in vivo by survivin targeting. Grossman, D., Kim, P.J., Schechner, J.S., Altieri, D.C. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  9. Protease receptors in Hodgkin's disease: expression of the factor Xa receptor, effector cell protease receptor-1, in Reed-Sternberg cells. Adida, C., Ambrosini, G., Plescia, J., Crotty, P.L., Costa, J., Altieri, D.C. Blood (1996) [Pubmed]
  10. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Mahlamäki, E.H., Bärlund, M., Tanner, M., Gorunova, L., Höglund, M., Karhu, R., Kallioniemi, A. Genes Chromosomes Cancer (2002) [Pubmed]
  11. Mitotic arrest, apoptosis, and sensitization to chemotherapy of melanomas by methionine deprivation stress. Kokkinakis, D.M., Brickner, A.G., Kirkwood, J.M., Liu, X., Goldwasser, J.E., Kastrama, A., Sander, C., Bocangel, D., Chada, S. Mol. Cancer Res. (2006) [Pubmed]
  12. Factor Xa activates endothelial cells by a receptor cascade between EPR-1 and PAR-2. Bono, F., Schaeffer, P., Hérault, J.P., Michaux, C., Nestor, A.L., Guillemot, J.C., Herbert, J.M. Arterioscler. Thromb. Vasc. Biol. (2000) [Pubmed]
  13. Xa receptor EPR-1. Altieri, D.C. FASEB J. (1995) [Pubmed]
  14. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. Storlazzi, C.T., Brekke, H.R., Mandahl, N., Brosjö, O., Smeland, S., Lothe, R.A., Mertens, F. J. Pathol. (2006) [Pubmed]
  15. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. Altieri, D.C. J. Biol. Chem. (1994) [Pubmed]
  16. CyclinB2 and BIRC5 genes as surrogate biomarkers for neurite outgrowth in SH-SY5Y subclonal cells. Oe, T., Nagashima, T., Muramoto, M., Yamazaki, T., Morikawa, N., Okitsu, O., Nishimura, S., Aoki, T., Katayama, Y., Kita, Y. Neuropharmacology (2006) [Pubmed]
  17. Contamination levels and preliminary assessment of the technical feasibility of employing natural attenuation in 5 priority areas of presidente bernardes refinery in cubatão, são paulo, Brazil. Schneider, R.P., Morano, S.C., Gigena, M.A., Missawa, S.K., Rocha, R.C., Silva, L.R., Ellert, N., Kataoka, S., Katsuragi, C., Rosa, C.d.a. .S., Filho, L.C. Environmental monitoring and assessment. (2006) [Pubmed]
  18. p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Hopkins-Donaldson, S., Belyanskaya, L.L., Simões-Wüst, A.P., Sigrist, B., Kurtz, S., Zangemeister-Wittke, U., Stahel, R. Neoplasia (2006) [Pubmed]
  19. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Mesri, M., Morales-Ruiz, M., Ackermann, E.J., Bennett, C.F., Pober, J.S., Sessa, W.C., Altieri, D.C. Am. J. Pathol. (2001) [Pubmed]
  20. Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias. Bowen, A.R., Hanks, A.N., Murphy, K.J., Florell, S.R., Grossman, D. The American Journal of dermatopathology. (2004) [Pubmed]
WikiGenes - Universities